Matches in Wikidata for { <http://www.wikidata.org/entity/Q59652447> ?p ?o ?g. }
- Q59652447 description "2016 թվականի հոկտեմբերի 10-ին հրատարակված գիտական հոդված" @default.
- Q59652447 description "artículu científicu espublizáu n'ochobre de 2016" @default.
- Q59652447 description "im Oktober 2016 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59652447 description "scientific article published on 10 October 2016" @default.
- Q59652447 description "wetenschappelijk artikel" @default.
- Q59652447 description "наукова стаття, опублікована в жовтні 2016" @default.
- Q59652447 name "SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I" @default.
- Q59652447 name "SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I" @default.
- Q59652447 type Item @default.
- Q59652447 label "SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I" @default.
- Q59652447 label "SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I" @default.
- Q59652447 prefLabel "SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I" @default.
- Q59652447 prefLabel "SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I" @default.
- Q59652447 P1433 Q59652447-33835720-1964-4963-B198-16B50A2D7F79 @default.
- Q59652447 P1476 Q59652447-43C82050-EEB1-4014-A70B-28101DBBC46F @default.
- Q59652447 P2093 Q59652447-0EFDB49D-1636-4D89-A84A-2640B961C90D @default.
- Q59652447 P2093 Q59652447-1E258908-78D2-4614-91EB-059673D67470 @default.
- Q59652447 P2093 Q59652447-2ED31AB0-2965-4801-8A72-59831051ADEA @default.
- Q59652447 P2093 Q59652447-3D5FA605-1D6D-45F7-B5F4-EC91F7148308 @default.
- Q59652447 P2093 Q59652447-428652F9-925E-497A-B4CD-2F7BECD83099 @default.
- Q59652447 P2093 Q59652447-42E35356-250B-42CA-9DD3-2E1C6A8F398C @default.
- Q59652447 P2093 Q59652447-4BFE94DC-2466-49C4-8F80-265D0C6E7D54 @default.
- Q59652447 P2093 Q59652447-7E8EACE8-B377-446D-A78A-32D6FFEB7A09 @default.
- Q59652447 P2093 Q59652447-84859014-0FAF-46E2-973F-D94FA0C1C9F1 @default.
- Q59652447 P2093 Q59652447-95F4DE1E-1CF0-47CB-9C17-146201695FA6 @default.
- Q59652447 P2093 Q59652447-9B3A8253-009C-41B2-923C-B2BF03FBD9A6 @default.
- Q59652447 P2093 Q59652447-A224EE77-6C1B-4E7F-8C48-312E2945A878 @default.
- Q59652447 P2093 Q59652447-A2841FDE-9025-4588-B1CC-427C5E1C32B7 @default.
- Q59652447 P2093 Q59652447-CBF4A656-1701-4AB7-8C34-FD04CF170C07 @default.
- Q59652447 P2093 Q59652447-CD66B487-69EC-4990-AC14-12F21D4C1089 @default.
- Q59652447 P2093 Q59652447-DBD81019-2966-46A4-BADF-1974FFB1134E @default.
- Q59652447 P2093 Q59652447-E33F99E0-4BB8-45F2-BB3C-6A6FEFAE3256 @default.
- Q59652447 P2093 Q59652447-F72EAD96-8D2E-4EBF-BA3A-A54D719E1AE0 @default.
- Q59652447 P2860 Q59652447-108B2E5C-411C-4119-9A82-E0CD99758557 @default.
- Q59652447 P2860 Q59652447-1199BF80-31FA-450C-ADA6-9E6631B48B11 @default.
- Q59652447 P2860 Q59652447-20F16946-EC39-4034-B2BF-0679E55D21AD @default.
- Q59652447 P2860 Q59652447-247FF9C3-2A40-40DE-A788-6C47076E66D0 @default.
- Q59652447 P2860 Q59652447-4256C4C0-ECCE-4F48-B4FE-1D27F78AE009 @default.
- Q59652447 P2860 Q59652447-4C10CA9B-AB38-41FE-88EB-5BB4B63E8F7B @default.
- Q59652447 P2860 Q59652447-4EB9922D-CCB7-4282-B748-A1C899E93FF6 @default.
- Q59652447 P2860 Q59652447-52708BAA-E282-4819-9142-86C3A4B98D7B @default.
- Q59652447 P2860 Q59652447-54DCEE2B-6726-482F-80A2-9DE245AE8BF3 @default.
- Q59652447 P2860 Q59652447-5803C60F-7574-45D3-9B92-6B303FE6D0FE @default.
- Q59652447 P2860 Q59652447-58087C97-8F4E-43C0-A7AC-E580678AA131 @default.
- Q59652447 P2860 Q59652447-61EFD951-5AC8-4777-A908-92625943B4FA @default.
- Q59652447 P2860 Q59652447-663D4F92-F102-41D4-9D0F-70A0CCE07113 @default.
- Q59652447 P2860 Q59652447-80BF1FBE-863D-4145-B5FA-B63E5F080AD7 @default.
- Q59652447 P2860 Q59652447-A7F4BBC4-C25D-47CA-BA26-CEC17F935383 @default.
- Q59652447 P2860 Q59652447-BD03719E-20D9-46F0-B0F1-1117EFCF4C6B @default.
- Q59652447 P2860 Q59652447-C74EEE24-F107-4539-AC78-B639F9E9F04B @default.
- Q59652447 P2860 Q59652447-D26E93A2-1760-4EEA-8FD0-33732B5C7C70 @default.
- Q59652447 P2860 Q59652447-D619075E-69BE-4F57-877B-6B196DCA4047 @default.
- Q59652447 P2860 Q59652447-E2585C9A-C606-4C59-8C79-4F44641AE37C @default.
- Q59652447 P2860 Q59652447-E94AC1AB-6D03-4BB4-88F8-EAA0C3D1ACA9 @default.
- Q59652447 P2860 Q59652447-E9C8F706-78CD-43A7-A9F1-CB207875C02D @default.
- Q59652447 P2860 Q59652447-ED83D1CB-647A-43F6-9F21-27B0A24F8E6E @default.
- Q59652447 P2860 Q59652447-EEB6A46B-CAB5-4082-ACFC-8923A3C981AF @default.
- Q59652447 P2888 Q59652447-FD6DE8E5-CE9C-4A85-8F07-3949CF02366D @default.
- Q59652447 P304 Q59652447-53DC1C91-2E89-4272-9180-A5AB561BDD28 @default.
- Q59652447 P31 Q59652447-70259091-0C06-4127-81A6-978F453EC0D7 @default.
- Q59652447 P356 Q59652447-508E5D1B-DE49-4B24-9CA6-FF9CF3AE53C7 @default.
- Q59652447 P407 Q59652447-0F690853-842A-40A2-8A78-08B3875DC2DC @default.
- Q59652447 P433 Q59652447-4AAB1EEC-97F5-43B2-B15E-10D6552A1661 @default.
- Q59652447 P478 Q59652447-2EE64063-4347-4FD8-AD53-BA61BC80E4BB @default.
- Q59652447 P50 Q59652447-04230547-A91E-42C3-8542-14623F33D306 @default.
- Q59652447 P50 Q59652447-9825E2A4-7893-4AF2-AF55-A2804A3C0F96 @default.
- Q59652447 P50 Q59652447-C043EC8C-1E5B-4BF8-AC57-F93B41077015 @default.
- Q59652447 P50 Q59652447-CDEBA21E-44F7-454B-A8A5-143443C6366A @default.
- Q59652447 P577 Q59652447-7EE651A0-9262-4E30-960F-93C9F01541B6 @default.
- Q59652447 P6179 Q59652447-42D889AA-CC37-43CD-ADCA-AFD17DBA6A4A @default.
- Q59652447 P698 Q59652447-3B27C3C1-2491-432A-9BB0-E83A868F3130 @default.
- Q59652447 P921 Q59652447-4319860f-40ec-7759-256c-80269d7598ae @default.
- Q59652447 P921 Q59652447-7E22CBD3-1364-4E6D-8607-D1675F87A30F @default.
- Q59652447 P921 Q59652447-8DC284D0-3F9C-473E-A901-B3DE932AB00C @default.
- Q59652447 P921 Q59652447-BC1E4220-E4B1-40A9-8B80-073002E1B94C @default.
- Q59652447 P932 Q59652447-4B6251DD-E680-4A2B-9D97-406C09018693 @default.
- Q59652447 P356 S12885-016-2823-Y @default.
- Q59652447 P698 27724870 @default.
- Q59652447 P1433 Q326300 @default.
- Q59652447 P1476 "SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial" @default.
- Q59652447 P2093 "Andreas Müller" @default.
- Q59652447 P2093 "Andreas Trojan" @default.
- Q59652447 P2093 "Daniel Rauch" @default.
- Q59652447 P2093 "Daniela Bärtschi" @default.
- Q59652447 P2093 "Jürg Bernhard" @default.
- Q59652447 P2093 "Khalil Zaman" @default.
- Q59652447 P2093 "Kyung-Jae Na" @default.
- Q59652447 P2093 "Marc Küng" @default.
- Q59652447 P2093 "Marcus Vetter" @default.
- Q59652447 P2093 "Markus Borner" @default.
- Q59652447 P2093 "Martin Bigler" @default.
- Q59652447 P2093 "Ralph Winterhalder" @default.
- Q59652447 P2093 "Richard Cathomas" @default.
- Q59652447 P2093 "Roger von Moos" @default.
- Q59652447 P2093 "Sandro Anchisi" @default.
- Q59652447 P2093 "Tamara Rordorf" @default.
- Q59652447 P2093 "Thomas Ruhstaller" @default.
- Q59652447 P2093 "Ursula Hasler-Strub" @default.
- Q59652447 P2860 Q27860904 @default.
- Q59652447 P2860 Q29614302 @default.